Clinical Trials

Showing 241 - 260 of 495 trials
Titlesort icon Investigator Disease(s)
A Phase II Study of LEE011 plus MEK162 in Patients with NRAS-Mutant Melanoma
[Protocol 13-102]
Postow, Michael
  • Melanoma
A Phase II Study of Lenalidomide Intensification in Patients with Asymptomatic Multiple Myeloma that Has Progressed with Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation
Newly Diagnosed
[Protocol 11-107]
Hassoun, Hani
  • Hematology
    • Multiple Myeloma
A Phase II Study of LGX818 Given in a Pulsatile Schedule to Patients with Stage III or IV Melanoma with a BRAF Mutation
[Protocol 13-053]
Chapman, Paul
  • Melanoma
A Phase II Study of LGX818 plus a Second Investigational Drug in Patients with Locally Advanced or Metastatic Melanoma that Continued to Grow on LGX818 Alone
[Protocol 13-233]
Postow, Michael
  • Melanoma
A Phase II Study of Midostaurin to Prevent Relapse After Allogeneic Stem Cell Transplantation in Patients with FLT3-ITD Mutated Acute Myeloid Leukemia
[Protocol 13-242]
Papadopoulos, Esperanza
  • Leukemia
    • Acute Myelocytic Leukemia
    • Acute Myelogenous Leukemia
A Phase II Study of Minimally Invasive Surgery Followed by Radiation and Chemotherapy versus Higher Dose Radiation and Chemotherapy for Patients with HPV-Negative Oropharynx Cancer
Relapsed/Refractory
[Protocol 14-038]
Ganly, Ian
  • Head & Neck Cancer
A Phase II Study of MLN0128 in Men with Castration-Resistant Prostate Cancer
[Protocol 13-143]
Rathkopf, Dana
  • Prostate Cancer
    • Metastatic Disease after Hormone-Reducing Therapy
A Phase II Study of MLN8237 in Advanced or Metastatic Sarcoma
[Protocol 12-194]
Dickson, Mark
  • Sarcomas
    • Soft Tissue Sarcoma
A Phase II Study of MLN8237 in Patients with Advanced Prostate Cancer
[Protocol 13-042]
Danila, Daniel
  • Prostate Cancer
    • Metastatic Disease after Hormone-Reducing Therapy
A Phase II Study of MPDL3280A Alone or with Bevacizumab versus Sunitinib Alone in Patients with Previously Untreated Advanced Renal Cell Cancer
[Protocol 13-212]
Motzer, Robert
  • Kidney Cancer
A Phase II Study of MPDL3280A in Patients with Locally Advanced or Metastatic Urothelial Bladder Cancer
[Protocol 14-090]
Rosenberg, Jonathan
  • Bladder Cancer
A Phase II Study of MPDL3280A in Patients with PD-L1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
[Protocol 14-024]
Chaft, Jamie
  • Lung Cancer, Non-Small Cell
A Phase II Study of Multi-Beam Intensity-Modulated Radiation Therapy for Patients with Locally Advanced Breast Cancer Who Had Implant Reconstruction
[Protocol 14-028]
Ho, Alice
  • Breast Cancer
A Phase II Study of Neoadjuvant Dose-Dense Gemcitabine and Cisplatin in Patients with Muscle-Invasive Bladder Cancer
[Protocol 12-071]
Bajorin, Dean
  • Bladder Cancer
A Phase II Study of Neoadjuvant Pemetrexed Plus Cisplatin for Patients with Resectable Non-Squamous Non-Small Cell Lung Cancer with "Switch Chemotherapy Alternative" in Non-Responders (NEOSCAN)
[Protocol 11-106]
Chaft, Jamie
  • Lung Cancer
  • Lung Cancer, Non-Small Cell
    • Lung Adenocarcinoma
A Phase II Study of Neratinib Alone and with Temsirolimus in Patients with Non-Small Cell Lung Cancer with HER2 Mutations
[Protocol 13-087]
Kris, Mark
  • Lung Cancer, Non-Small Cell
A Phase II Study of Neratinib in Patients with Solid Tumors Containing Mutated HER2
[Protocol 13-140]
Hyman, David
  • Bladder Cancer
  • Colorectal Cancer
  • Ovarian Cancer
  • Solid Tumors
  • Upper Gastrointestinal
    • Esophageal Cancer
    • Gastric Cancer
  • Uterine (Endometrial) Cancer
A Phase II Study of Nivolumab plus Ipilimumab versus Ipilimumab Alone in Patients with Previously Untreated Inoperable or Metastatic Melanoma
[Protocol 13-169]
Postow, Michael
  • Melanoma
A Phase II Study of Paclitaxel, Trastuzumab, and Pertuzumab for the Treatment of Metastatic HER2-Positive Breast Cancer
[Protocol 10-142]
Dang, Chau
  • Breast Cancer
A Phase II Study of Paclitaxel/Carboplatin versus Bleomycin/Etoposide/Cisplatin for Patients with Advanced Ovarian Stromal Tumors Who Have Not Received Chemotherapy
Relapsed/Refractory
[Protocol 13-177]
Leitao, Mario
  • Ovarian Cancer